TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06146361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Group Problem Solving
Description: This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Group Problem Solving
Description: This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: This group will receive a COVID-19 prevention flyer and social resources list only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: This group will receive a COVID-19 prevention flyer and social resources list only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This group will receive a COVID-19 prevention flyer and social resources list only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster session
Description: Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention.
Study: NCT05649319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
Study: NCT05515497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMT4me 2.0 app
Description: The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
Study: NCT06290648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forging New Paths
Description: The study intervention is Forging New Paths (FNP) a newly developed intervention for people with mental illness with criminal legal system involvement that is designed to be delivered in community mental health settings. FNP combines Cognitive Behavioral Treatment (CBT) techniques with social learning principles in a group format. The intervention is organized into a modular format to create a flexible intervention structure. It includes 5 treatment modules each consisting of two to four group sessions for a total of 14-16 sessions, which may be delivered over multiple meetings at the facilitators' discretion. The intervention is designed to be delivered to 8-12 people by two intervention facilitators. It can be delivered in person, virtually, or in a hybrid format.
Study: NCT05751564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product
Description: Cryopreserved thaw \& inject MSC intra-articular therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product
Description: Cryopreserved resuspended MSC intra-articular therapy
Study: NCT05581524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VASC
Description: At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
Study: NCT06088472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL injection
Description: Autologous tumor infiltrating lymphocyte injection
Study: NCT04909918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
Study: NCT05593263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical correction of astigmatism with cataract
Description: The Steep meridian will be identified and marked, relaxing limbal / corneal incisions will be designed according to it.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical correction of astigmatism with cataract
Description: The Steep meridian will be identified and marked, relaxing limbal / corneal incisions will be designed according to it.
Study: NCT06027957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T-cells
Description: For Biological: CD19 CAR T-cells~* Dose: 1-2.10e6 cells/kg of weight~* Route: intravenous infusion~For Chemotherapy Drug:~* Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~* Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~* Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after.
Study: NCT05208840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
Study: NCT05648032

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lyophilized platelet (30ng) and triamcinolone acetonide 10mg
Description: Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lyophilized platelet (30ng)
Description: Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide 10mg
Description: Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
Study: NCT06520410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with a 18 mm short vitrector
Description: Using the shorter 18 mm vitrector for various pediatric vitreoretinal surgeries
Study: NCT04702919

Intervention type: OTHER
Intervention: Registration
Description: Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.

Intervention type: OTHER
Intervention: Auditive oddball task
Description: Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
Study: NCT06032325

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Gelatinase and Kidney Injury Molecule-1
Description: To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
Study: NCT05287451

Intervention type: OTHER
Group type: OTHER
Intervention: RIsk-Reducing Salpingectomy (RRS)
Description: complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Risk-Reducing Oophorectomy-RRO
Description: complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
Study: NCT04780919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-6000 FSWT
Description: Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-6000 FSWT with sham applicator
Description: Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
Study: NCT05256407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention, digital support
Description: Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
Study: NCT05182151

Intervention type: DRUG
Intervention: Istradefylline 40 mg
Description: adenosine A2A receptor antagonist
Study: NCT04865068

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography measures on SSA participants
Description: Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards
Study: NCT04942925

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Kalifilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Kalifilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear
Study: NCT04907760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized care program
Description: It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
Study: NCT06108895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ilio-inguinal/ilio-hypogastric nerve block (IINB)
Description: Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: 200 mcg morphine intrathecally with bupivacaine
Study: NCT06281184

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate 10-20 mg x 1 per week, combined with folic acid 1mg daily.

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate 10-20 mg x 1 per week, combined with folic acid 1mg daily.

Intervention type: OTHER
Intervention: No treatment
Description: No specific treatment after MERINO-trial

Intervention type: OTHER
Intervention: No treatment
Description: No specific treatment after MERINO-trial
Study: NCT05677555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Study: NCT06267196

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The use of a stress ball
Description: The effect of the stress ball used during spinal anesthesia on pain and anxiety
Study: NCT05424653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve System
Description: Procedure: Transcatheter Aortic Valve Replacement
Study: NCT04314856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FTC-146
Description: 18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FTC-146
Description: 18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
Study: NCT03976973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interventional radiology insertion of drain
Description: Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
Study: NCT05125237

Intervention type: DRUG
Intervention: Amiloride
Description: Amiloride claim is used as the exposure group.

Intervention type: DRUG
Intervention: Triamterene
Description: Triamterene claim is used as the reference group.
Study: NCT05711290

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxygen Nanobubble
Description: This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Nanobubble
Description: This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
Study: NCT01344928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT exercise intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise intervention
Study: NCT05456672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meals and food baskets
Description: Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)
Study: NCT05026398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
Study: NCT05735431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of investigation drug
Description: Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of comparator
Description: Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
Study: NCT05374538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration
Study: NCT05395442

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Training on web-based diabetic foot care based on the Health Belief Model
Description: Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
Study: NCT05374538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Sotorasib tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Sotorasib tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Sotorasib tablets for oral administration
Study: NCT06372561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate (dressing material)
Description: MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (dressing material)
Description: MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin (dressing material)
Description: melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin (dressing material)
Description: melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
Study: NCT04834596

Intervention type: OTHER
Intervention: retrospectives analysis on hepatic scanner
Description: hepatic scanner will be analysed by two radiologist and by the software

Intervention type: OTHER
Intervention: retrospectives analysis on hepatic scanner
Description: hepatic scanner will be analysed by two radiologist and by the software

Intervention type: OTHER
Intervention: retrospectives analysis on hepatic scanner
Description: hepatic scanner will be analysed by two radiologist and by the software